AVTX — Avalo Therapeutics, Inc.
Fresh Supply424B filed ~75d ago🖨 Heavy Printer🌀 Serial Splitter📄 Fresh Paper1-for-2,209 cumulative
XBRL EDGAR
424B filed ~75d ago
Case Notes
Avalo Therapeutics, Inc. has 2 reverse splits on record — cumulative 1-for-2,209. Its share count grew 385.5% over the last twelve months per XBRL EDGAR data.
Most recent stress filing: 10-Q on 2026-05-13, flagging no specific flags. 1 supply registration (S-1/424B) landed in the last 12 months.
Registered shares exist to be sold — that is what the S-1 and 424B instruments document. In our research across this filing posture, freshly registered supply is the loaded state of the cycle: the paperwork has created the legal right to place shares into the market. That is not a prediction — it is what the filings say is possible.
Share Count Over Time
XBRL cover-page share counts from SEC EDGAR filings. Amber dashed lines mark reverse-split dates. 2 reverse splits on record.
Reverse Split Log
Each event consolidates shares — fewer shares, same market cap. Source: EDGAR corporate actions.
Cumulative effective ratio: 1-for-2,209— a share held at inception is now worth 1/2,209 of its original fraction.
Filing Stress Record
Stress-language flags extracted from SEC EDGAR 10-K/10-Q filings. Score 1–10 reflects language intensity.
| Date | Form | Score | Flags |
|---|---|---|---|
| 2024-08-12 | 10-Q | 2/10 | Going concernSplit intent |
| 2024-11-07 | 10-Q | 2/10 | Going concernSplit intent |
| 2025-03-20 | 10-K | 2/10 | Capital needListing compliance |
| 2025-05-12 | 10-Q | 2/10 | ATM/ELOCSplit intent |
| 2025-08-07 | 10-Q | 2/10 | ATM/ELOCSplit intent |
| 2025-11-06 | 10-Q | 0/10 | |
| 2026-03-23 | 10-K | 2/10 | Capital needListing compliance |
| 2026-05-13 | 10-Q | 0/10 |
Source: public EDGAR records.
424B Supply Pulse
Prospectus supplements (424B5) filed registering shares for resale — each bar is one month with a filing. Bars above average signal active distribution windows. Source: SEC EDGAR.